One-Liner
A personal photo and symptom journal for consumers on new medications that AI-matches their personal timeline against FDA pharmacovigilance signal patterns for that drug.
AI Thinking Process
Scale Shift: institutional post-marketing pharmacovigilance signal detection (FDA FAERS + EMA EudraVigilance) → personal medication side-effect journal. Consumer takes weekly photos, tracks health metrics, AI matches against FAERS signals for their specific drug.
Idea history contains 'Consumer Adverse Drug Event Group-Complaint Tool.' Same underlying FAERS data, same consumer-side observation, different UI (individual longitudinal vs group complaint). Not sufficiently novel.
Accuracy Cliff: consumer-side pharmacovigilance requires near-perfect accuracy. Without it, downgrades to diary tool with no value beyond a spreadsheet.
Adoption barrier (structural adoption barrier): patients on new medications want reassurance the drug is working, not side-effect surfacing. Actively surfacing patterns creates anxiety without actionability.
Killed by duplicate adjacency + accuracy cliff + adoption barrier. G212 12/12 result: zero Scale Shift survivors this session — consistent with all prior 11 capability sessions.
Kill Reason
Three-way kill: (1) duplicate adjacency to existing 'Consumer Adverse Drug Event Group-Complaint Tool' in idea history — same underlying FDA FAERS data, same consumer-side observation, insufficient novelty; (2) accuracy cliff — consumer-side pharmacovigilance requires near-perfect accuracy or downgrades to a diary tool with no actionable value; (3) adoption barrier (structural adoption barrier) — patients on new medications frequently do not want more side-effect information; they want reassurance that the drug is working. G212 Scale Shift 12/12 formal decision: zero Scale Shift survivors again.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.